Capricor Therapeutics (NASDAQ: CAPR) Faces Headwinds: Lawsuit and FDA Review Extension Impact Biotech Stock

• Capricor Therapeutics received a "Neutral" rating from H.C. Wainwright, reflecting significant uncertainty surrounding the biotechnology company.
• The company is embroiled in a securities class action lawsuit over alleged data integrity issues in its HOPE-3 study.
• The U.S. Food and Drug Administration (FDA) has extended its review of Deramiocel, pushing the PDUFA target action date to November 22, 2026, contributing to a sharp stock value decline.

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company developing cell therapies for diseases. Its main focus is on Deramiocel, a treatment for Duchenne muscular dystrophy (DMD). On August 24, 2026, analyst firm H.C. Wainwright confirmed its "Neutral" rating on Capricor Therapeutics, indicating a "hold" position when the stock price was $7.09.

This neutral stance reflects significant uncertainty surrounding the biotech company. Capricor Therapeutics is currently facing a securities class action lawsuit initiated by Levi & Korsinsky, LLP, as highlighted by GlobeNewswire. The lawsuit is for investors who purchased securities between December 17, 2025, and July 26, 2026, adding a layer of legal risk to the Capricor Therapeutics stock outlook.

The lawsuit follows allegations that FDA briefing documents revealed unagreed changes to the statistical analysis plan for Capricor Therapeutics' HOPE-3 study. This has caused analysts to question the integrity of the clinical trial data, which previously showed positive results for the study's primary and secondary goals.

These issues triggered a sharp decline in Capricor Therapeutics' stock value. Capricor Therapeutics shares fell 78.70% after the allegations surfaced. The biotech stock, which had reached a high of $35.34, dropped to $7.00 on July 27, 2026, and then fell further to $4.19 just days later, impacting investor confidence.

Adding to the uncertainty, the U.S. Food and Drug Administration (FDA) has extended its review of Deramiocel. The Prescription Drug User Fee Act (PDUFA) target action date, which is the deadline for the FDA to decide on a drug's approval, is now November 22, 2026, as reported by Reuters. This FDA review extension further contributes to the Capricor Therapeutics stock volatility.